Vedolizumab Induction May Prevent Celiac Enteritis
Status:
Terminated
Trial end date:
2018-10-05
Target enrollment:
Participant gender:
Summary
Celiac disease (CD) is characterized as an autoimmune disorder whereby gluten (a protein
found in wheat, barley, rye, malt) induces an immunological response in genetically
susceptible individuals. The prevalence of CD has been estimated to affect 0.5-1% of the
population worldwide. Long term sequelae are numerous and include risk of lymphoma,
malabsorption leading to weight loss, anemia, multiple vitamin deficiencies,
osteoporosis/osteopenia, secondary autoimmunity, etc. (1)